Jones Trading Starts iBio, Inc. (IBIO) at Buy Mar 2, 2026 04:16PM
iBio, Inc. (IBIO) reported Q2 EPS Feb 11, 2026 12:29AM
iBio, Inc. (IBIO) files for 11.06M share offering by selling stockholders Jan 30, 2026 04:13PM
iBio reports extended half-life data for obesity drug candidate Oct 30, 2025 07:00AM
Oppenheimer Starts iBio, Inc. (IBIO) at Outperform, PT $5 Oct 20, 2025 04:07PM


Sep 5, 2025 01:01PM Brookline Capital Markets Reiterates Buy Rating on iBio, Inc. (IBIO)
Aug 27, 2025 04:37PM iBio, Inc. (IBIO) PT Lowered to $1.60 at Brookline Capital Markets
Jun 25, 2025 07:58AM Chardan Comments on iBio, Inc. (IBIO)
Jun 23, 2025 04:15PM iBio, Inc. (IBIO) Presents Next-Generation Obesity and Cardiometabolic Pipeline Candidates
Jun 16, 2025 07:03AM iBio (IBIO) Initiates Non-Human Primate Study of First-in-Class Activin E Antibody Following Positive Preclinical Data Demonstrating Prevention in Weight Regain After GLP-1 Treatment
Jun 13, 2025 09:04AM iBio, Inc. (IBIO) Files for 11.25M Share Offering by Selling Stockholders
Apr 29, 2025 01:44PM iBio, Inc. (IBIO) Raises $6.2M Through Warrant Inducement Transaction
Apr 22, 2025 08:02AM iBio, Inc. (IBIO) Expands Cardiometabolic and Obesity Pipeline through Licensing of First-in-Class Antibody Targeting Activin E from AstralBio
Apr 7, 2025 07:00AM iBio, Inc. (IBIO) Announces IBIO-600 Non-Human Primate Data Showing Extended Half-Life and Muscle Growth
Jan 7, 2025 07:01AM iBio, Inc. (IBIO) Discovers Novel Antibody Targeting Activin E in Collaboration with AstralBio
Aug 12, 2024 04:31PM iBio, Inc. (IBIO) Appoints Kristi Sarno as VP of Business Development
Jul 25, 2024 05:14PM iBio, Inc. (IBIO) Files $150M Mixed Shelf
Jul 22, 2024 08:30AM Brookline Capital Markets Starts iBio, Inc. (IBIO) at Buy